CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,046 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04941027
NCT04941027N/ACompleted
CompareCT.gov

Evaluating Genetic Modifiers of Cutaneous Neurofibromas in Adults With Neurofibromatosis Type 1

Stanford University·observational·Posted Jun 28, 2021·Updated Dec 2, 2025

In Brief

An observational study for Neurofibromatosis 1. Completed, enrolled 1,046 participants across 2 sites.

Detailed Summary

The main goal of this protocol is to develop a well-phenotyped genetic biobank to identify genetic variants associated with the heterogeneous clinical presentations of Neurofibromatosis Type 1 (NF1). This will allow for improve understanding of NF1 pathogenesis and more personalized disease management. The investigators will conduct a GWAS analysis to identify common genetic risk variants associated with the development of cutaneous neurofibromas.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsNeurofibromatosis 1
CountriesUnited States
CollaboratorsJohns Hopkins University, University of California, San Francisco

Timeline

N/ACompletedFinished
20222023202420252026
First PostedJun 28, 2021
Enrollment StartMay 7, 2021
Primary CompletionSep 30, 2025
Study CompletionNov 24, 2025
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 5.0 years ago